Biomarkers in melanoma: Stage III and IV disease

References

• Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19, 3635–3648 (2001).
   PubMed Web of Science ®Google Scholar
• Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist8, 451–458 (2003).
   PubMed Web of Science ®Google Scholar
• de Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma. Crit. Rev. Oncol. Hematol.47, 35–63 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS. Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev. Mol. Diagn.3, 303–330 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson JA, Slominski A, Linette GP, Mihm MC Jr, Ross JS. Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev. Mol. Diagn.3, 163–184 (2003).
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19, 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry D IV et al. Model predicting survival in Stage I melanoma based on tumor progression. J. Natl Cancer Inst.81, 1893–1904 (1989).
   PubMed Web of Science ®Google Scholar
• Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum. Pathol.31, 327–331 (2000).
   PubMed Web of Science ®Google Scholar
• White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann. Surg.235, 879–887 (2002).
   PubMed Web of Science ®Google Scholar
• Chang AE, Karnell LH, Menck HR. The National Cancer Database report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer83, 1664–1678 (1998).
   PubMed Web of Science ®Google Scholar
• Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer91, 2401–2408 (2001).
   PubMedGoogle Scholar
• Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer77, 1303–1310 (1996).
   PubMed Web of Science ®Google Scholar
• Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest74, 43–47 (1996).
   PubMed Web of Science ®Google Scholar
• Healy E, Belgaid C, Takata M et al. Prognostic significance of allelic losses in primary melanoma. Oncogene16, 2213–2218 (1998).
   PubMedGoogle Scholar
• Pihan G, Doxsey SJ. Mutations and aneuploidy: co-conspirators in cancer? Cancer Cell4, 89–94 (2003).
   Google Scholar
• Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nature Rev. Mol. Cell. Biol.5, 45–54 (2004).
   PubMed Web of Science ®Google Scholar
• Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg.181, 193–201 (1995).
   PubMed Web of Science ®Google Scholar
• Sirott MN, Bajorin DF, Wong GY et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer72, 3091–3098 (1993).
   Google Scholar
• Eton O, Legha SS, Moon TE et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol.16, 1103–1111 (1998).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Conradt C, Legha SS et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J. Clin. Oncol.16, 2921–2929 (1998).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Martus P, Punt CJ et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin-2 (IL-2) with or without cisplatin. Eur. J. Cancer38, 1501–1511 (2002).
   PubMed Web of Science ®Google Scholar
• Deichmann M, Benner A, Bock M et al. S100-α, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer Stage IV melanoma. J. Clin. Oncol.17, 1891–1896 (1999).
   PubMed Web of Science ®Google Scholar
• Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J. Clin. Oncol.21, 187–193 (2003).
   Google Scholar
• Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and α-fetoprotein during therapy. J. Clin. Oncol.19, 2534–2541 (2001).
   PubMed Web of Science ®Google Scholar
• Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol.22, 537–556 (2004).
   PubMed Web of Science ®Google Scholar
• Proebstle TM, Jiang W, Hogel J, Keilholz U, Weber L, Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br. J. Cancer82, 118–123 (2000).
   PubMed Web of Science ®Google Scholar
• Slominski A, Goodman-Snitkoff GG. Dopa inhibits induced proliferative activity of murine and human lymphocytes. Anticancer Res.12, 753–756 (1992).
   PubMedGoogle Scholar
• Slominski A. Coming of age of melanogenesis-related proteins. Arch. Pathol. Lab. Med.126, 775–777 (2002).
   PubMedGoogle Scholar
• Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol.2, 205–211 (2001).
   PubMed Web of Science ®Google Scholar
• Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol.21, 2415–2432 (2003).
   PubMed Web of Science ®Google Scholar
• Morton DL, Foshag LJ, Hoon DS et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg.216, 463–482 (1992).
   PubMed Web of Science ®Google Scholar
• Chung MH, Gupta RK, Hsueh E et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J. Clin. Oncol.21, 313–319 (2003).
   PubMedGoogle Scholar
• Hsueh EC, Essner R, Foshag LJ. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol.20, 4549–4554 (2002).
   PubMed Web of Science ®Google Scholar
• Wascher RA, Morton DL, Kuo C et al. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J. Clin. Oncol.21, 2558–2563 (2003).
   PubMed Web of Science ®Google Scholar
• Sarantou T, Chi DD, Garrison DA et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res.57, 1371–1376 (1997).
   PubMedGoogle Scholar
• Mellado B, Del Carmen Vela M, Colomer D et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J. Clin. Oncol.20, 4032–4039 (2002).
   PubMedGoogle Scholar
• Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch. Dermatol.137, 325–330 (2001).
   PubMedGoogle Scholar
• Davies HBG, Cox C, Stephens P et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Gorden A, Osman I, Gai W et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res.63, 3955–3957 (2003).
   Google Scholar
• Cohen Y, Goldenberg-Cohen N, Parrella P et al. Lack of BRAF mutation in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci.44, 2876–2878 (2003).
   PubMed Web of Science ®Google Scholar
• Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer88, 1403–1405 (2003).
   PubMed Web of Science ®Google Scholar
• Laud K, Kannengiesser C, Avril MF et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res.63, 3061–3065 (2003).
   Google Scholar
• Meyer P, Klaes R, Schmitt C, Boettger MB, Garbe C. Exclusion of BRAFV599E as a melanoma susceptibility mutation. Int. J. Cancer106, 78–80 (2003).
   PubMedGoogle Scholar
• Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat.21, 327–330 (2003).
   PubMed Web of Science ®Google Scholar
• Lee JT, McCubrey JA. BAY-43–9006 Bayer/Onyx. Curr. Opin. Investig. Drugs4, 757–763 (2003).
   PubMedGoogle Scholar
• Flaherty K. A Phase I trial of BAY 43–9006 in combination with carboplatin and paclitaxel. ASCO Proc. Am. Soc. Clin. Oncol.(Abstract 2854) (2003).
   Google Scholar
• Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol.111, 757–761 (1998).
   PubMed Web of Science ®Google Scholar
• Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature406, 532–535 (2000).
   PubMed Web of Science ®Google Scholar
• Cook MG, Green MA, Anderson B et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J. Pathol.200, 314–319 (2003).
   PubMedGoogle Scholar
• Karakousis CP, Velez A, Driscoll DL, Takita H. Metastasectomy in malignant melanoma. Surgery115, 295–302 (1994).
   PubMedGoogle Scholar
• Wood TF, DiFronzo LA, Rose DM et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann. Surg. Oncol.8, 658–662 (2001).
   PubMedGoogle Scholar
• Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent Stage IV melanoma. J. Surg. Oncol.71, 209–213 (1999).
   PubMed Web of Science ®Google Scholar
• Lotem M, Peretz T, Drize O et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC Stages III and IV). The new American Joint Committee on Cancer. Br. J. Cancer86, 1534–1539 (2002).
   PubMed Web of Science ®Google Scholar
• Vlaykova T, Talve L, Hahka-Kemppinen M et al. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology62, 259–268 (2002).
   PubMed Web of Science ®Google Scholar
• Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet356, 1728–1733 (2000).
   PubMed Web of Science ®Google Scholar
• Heaton KM, Rippon MB, el-Naggar A, Tucker SL, Ross MI, Balch CM. Prognostic implications of DNA index in patients with stage III cutaneous melanoma. Am. J. Surg.166, 648–652 (1993).
   PubMedGoogle Scholar
• Sauter ER, Yeo UC, von Stemm A et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res.62, 3200–3206 (2002).
   PubMedGoogle Scholar
• Mu XC, Tran TA, Ross JS, Carlson JA. Topoisomerase II-α expression in melanocytic nevi and malignant melanoma. J. Cutan. Pathol.27, 242–248 (2000).
   PubMedGoogle Scholar
• Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch. Pathol. Lab. Med.125, 1295–1306 (2001).
   PubMed Web of Science ®Google Scholar
• de Vries TJ, Smeets M, de Graaf R et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Co-operative Group. J. Pathol.193, 13–20 (2001).
   PubMed Web of Science ®Google Scholar
• Gogas H, Kefala G, Bafaloukos D et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer87, 181–186 (2002).
   PubMed Web of Science ®Google Scholar
• Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of Stage I–III melanoma. J. Clin. Oncol.19, 1176–1182 (2001).
   PubMedGoogle Scholar
• Hauschild A, Engel G, Brenner W et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology56, 338–344 (1999).
   PubMedGoogle Scholar
• Mouawad R, Antoine EC, Gil-Delgado M, Khayat D, Soubrane C. Serum caspase-1 levels in metastatic melanoma patients: relationship with tumor burden and non-response to biochemotherapy. Melanoma Res.12, 343–348 (2002).
   PubMedGoogle Scholar
• Meral R, Duranyildiz D, Tas F et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res.11, 627–632 (2001).
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res.63, 441–448 (2003).
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Probst-Kepper M, Grosse J et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res.10, 355–362 (2000).
   PubMedGoogle Scholar
• Bystryn JC, Albrecht J, Reynolds SR et al. Decrease in circulating tumor cells as an early marker of therapy effectiveness. Recent Results Cancer Res.158, 204–207 (2001).
   PubMedGoogle Scholar
• Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff A. Comparison of two prognostic markers for malignant melanoma: MIA and S100 α. Tumour Biol22, 54–58 (2001).
   PubMed Web of Science ®Google Scholar
• Guba M, Steinbauer M, Ruhland V et al. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Oncol. Rep.9, 981–984 (2002).
   PubMedGoogle Scholar
• Franzke A, Probst-Kepper M, Buer J et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br. J. Cancer78, 40–45 (1998).
   PubMed Web of Science ®Google Scholar
• Stoitchkov K, Letellier S, Garnier JP et al. Melanoma progression and serum l-dopa/l-tyrosine ratio: a comparison with S100α. Melanoma Res.12, 255–262 (2002).
   PubMed Web of Science ®Google Scholar
• Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Naher H. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100 α or melanoma inhibitory activity (MIA)? Melanoma Res.11, 291–296 (2001).
   PubMedGoogle Scholar
• Karnell R, Kagedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res.10, 363–369 (2000).
   PubMedGoogle Scholar
• Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res.57, 5073–5076 (1997).
   PubMedGoogle Scholar
• Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol.25, 53–76 (2003).
   PubMedGoogle Scholar